

**REMARKS**

This amendment and remarks are in response to the Office Action of August 8, 2006. Claims 1, 3-11, 13 and 15-40 were in the case, but are herein cancelled without prejudice. New Claims 41-65 are added and find their support in the provisional application number 60/419,791, to which the pending application claims priority. The new claims reflect amendments to conform with the existing restriction requirement (Group II) wherein R<sup>4</sup> is R<sup>c</sup> and the central ring containing Q<sup>1</sup> and Q<sup>2</sup> is piperazine.

**35 U.S.C. § 112**

New Claims 41-65 have been provided and Applicants believe that the full scope of these claims is supported by the large number of examples, some of which are present in Claim 65.

**35 U.S.C. § 102(e)**

The previous claim set was rejected as being anticipated by Sun. The 102(e) date for Sun is December 24, 2002. New Claims 41-65 come directly from the provisional filing in this case which has a priority date of October 17, 2002. Accordingly, Sun is removed as a reference from these claims.

**35 U.S.C. § 103(a)**


The previous claim set was rejected as being obvious in light of Sun. The 102(e) date for Sun is December 24, 2002. New Claims 41-65 come directly from the provisional filing in this case which has a priority date of October 17, 2002. Accordingly, Sun is removed as a reference from these claims.

Applicants' attorney sincerely and respectfully requests that the Examiner consider, a telephone (805-447-3299) or personal interview to resolve any outstanding issues deemed appropriate by the Examiner.

Please send all future correspondence to:

US Patent Operations/RVP  
Dept. 4300, M/S 28-2-C  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,



Richard V. Person  
Attorney for Applicants  
Registration No.: 42,991  
Phone: (805) 447-3299  
Date: January 10, 2007